Xie Jian 4
4 · Fulgent Genetics, Inc. · Filed Apr 28, 2026
Research Summary
AI-generated summary of this filing
Fulgent Genetics (FLGT) COO Jian Xie Shares Withheld for Taxes
What Happened
- Jian Xie, President and Chief Operating Officer of Fulgent Genetics (FLGT), had 4,361 shares withheld to satisfy tax withholding obligations on vested restricted stock units. The shares were valued at $16.31 each for a total of $71,128. This is a tax-withholding disposition (transaction code F), a routine administrative action rather than a discretionary open-market sale.
Key Details
- Transaction date: 2026-04-26; Filing date: 2026-04-28 (filed timely).
- Price per share: $16.31; Shares withheld/disposed: 4,361; Total value: $71,128.
- Shares owned after transaction: Not disclosed in this filing.
- Footnote F1: Shares were withheld to satisfy tax obligations on RSUs assumed under the merger agreement dated Nov 7, 2022; the original awards were reported on Form 4 filed Nov 9, 2022.
- Footnote F2: Some securities are held by The Hsieh Family Dynasty Trust (dated Jan 27, 2010). Mr. Xie serves on the trust’s investment committee and disclaims beneficial ownership except for any pecuniary interest.
Context
- This was a tax-withholding (cashless) disposition tied to RSU vesting, not an intentional investment sale; such withholdings are common and typically do not indicate insider sentiment about the company’s stock.
- The filing appears timely under Form 4 rules (reported within two business days of the transaction).
Insider Transaction Report
Form 4
Xie Jian
President and COO
Transactions
- Tax Payment
Common Stock
[F1]2026-04-26$16.31/sh−4,361$71,128→ 370,952 total
Holdings
- 220,816(indirect: By Trust)
Common Stock
[F2]
Footnotes (2)
- [F1]The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.
- [F2]Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.
Signature
/s/ Paul Kim as Attorney-in-Fact|2026-04-28